Beta-blockers: Physiological, pharmacological and therapeutic implications

Research output: Book/ReportBook

Abstract

In the late 1950s, Sir James Black made a tremendous contribution to pharmacology and medicine with his discovery of â-blockers. After the first â-blockers became available in the 1960s, these drugs were noted to have beneficial effects in reducing morbidity and mortality from ischemic heart disease. It soon thereafter became apparent that blocking the adverse effects of the sympathetic nervous system could benefit many other diseases. As research and development continued, later generations of â-blockers appeared, each with unique properties such that it is now impossible to group these agents into one class to uniformly describe their effects. In this edition of Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications, the authors examine how â-blockers have evolved from their origin as a treatment for angina to a myriad of other elated and unrelated medical conditions. These include (in order of appearance), heart failure, hypertension, sepsis, tachydysrhythmias, portal hypertension, variceal bleeding, stimulant toxicity, thyrotoxicosis, obstructive lung disease, trauma, pheochromocytoma, cancer, acute coronary syndromes, and coronary arterial disease. The authors of these chapters hail from a spectrum of medical specialties as diverse as the indications for â-blockers: anesthesiology, cardiology, critical care, emergency medicine, gastroenterology, hematology/oncology, internal medicine, pharmacology, pulmonology, surgery, and toxicology. In this book, we also discuss controversies as well as the evolving and changing indications and contraindications for the use of this amazing class of drugs. This book will be of interest to physicians, pharmacists, nurse practitioners, physician assistants, nurses, research scientists, and informed patients.

Original languageEnglish (US)
PublisherNova Science Publishers, Inc.
Number of pages314
ISBN (Electronic)9781536133127
ISBN (Print)9781536133110
StatePublished - Jan 1 2018

Fingerprint

Pharmacology
Medicine
Obstructive Lung Diseases
Physician Assistants
Pulmonary Medicine
Thyrotoxicosis
Anesthesiology
Nurse Practitioners
Emergency Medicine
Sympathetic Nervous System
Portal Hypertension
Pheochromocytoma
Hematology
Gastroenterology
Critical Care
Acute Coronary Syndrome
Internal Medicine
Cardiology
Pharmacists
Research

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Beta-blockers : Physiological, pharmacological and therapeutic implications. / Richards, John R.

Nova Science Publishers, Inc., 2018. 314 p.

Research output: Book/ReportBook

@book{64ee28bd2692470c8ae79570d0835a87,
title = "Beta-blockers: Physiological, pharmacological and therapeutic implications",
abstract = "In the late 1950s, Sir James Black made a tremendous contribution to pharmacology and medicine with his discovery of {\^a}-blockers. After the first {\^a}-blockers became available in the 1960s, these drugs were noted to have beneficial effects in reducing morbidity and mortality from ischemic heart disease. It soon thereafter became apparent that blocking the adverse effects of the sympathetic nervous system could benefit many other diseases. As research and development continued, later generations of {\^a}-blockers appeared, each with unique properties such that it is now impossible to group these agents into one class to uniformly describe their effects. In this edition of Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications, the authors examine how {\^a}-blockers have evolved from their origin as a treatment for angina to a myriad of other elated and unrelated medical conditions. These include (in order of appearance), heart failure, hypertension, sepsis, tachydysrhythmias, portal hypertension, variceal bleeding, stimulant toxicity, thyrotoxicosis, obstructive lung disease, trauma, pheochromocytoma, cancer, acute coronary syndromes, and coronary arterial disease. The authors of these chapters hail from a spectrum of medical specialties as diverse as the indications for {\^a}-blockers: anesthesiology, cardiology, critical care, emergency medicine, gastroenterology, hematology/oncology, internal medicine, pharmacology, pulmonology, surgery, and toxicology. In this book, we also discuss controversies as well as the evolving and changing indications and contraindications for the use of this amazing class of drugs. This book will be of interest to physicians, pharmacists, nurse practitioners, physician assistants, nurses, research scientists, and informed patients.",
author = "Richards, {John R}",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781536133110",
publisher = "Nova Science Publishers, Inc.",

}

TY - BOOK

T1 - Beta-blockers

T2 - Physiological, pharmacological and therapeutic implications

AU - Richards, John R

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In the late 1950s, Sir James Black made a tremendous contribution to pharmacology and medicine with his discovery of â-blockers. After the first â-blockers became available in the 1960s, these drugs were noted to have beneficial effects in reducing morbidity and mortality from ischemic heart disease. It soon thereafter became apparent that blocking the adverse effects of the sympathetic nervous system could benefit many other diseases. As research and development continued, later generations of â-blockers appeared, each with unique properties such that it is now impossible to group these agents into one class to uniformly describe their effects. In this edition of Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications, the authors examine how â-blockers have evolved from their origin as a treatment for angina to a myriad of other elated and unrelated medical conditions. These include (in order of appearance), heart failure, hypertension, sepsis, tachydysrhythmias, portal hypertension, variceal bleeding, stimulant toxicity, thyrotoxicosis, obstructive lung disease, trauma, pheochromocytoma, cancer, acute coronary syndromes, and coronary arterial disease. The authors of these chapters hail from a spectrum of medical specialties as diverse as the indications for â-blockers: anesthesiology, cardiology, critical care, emergency medicine, gastroenterology, hematology/oncology, internal medicine, pharmacology, pulmonology, surgery, and toxicology. In this book, we also discuss controversies as well as the evolving and changing indications and contraindications for the use of this amazing class of drugs. This book will be of interest to physicians, pharmacists, nurse practitioners, physician assistants, nurses, research scientists, and informed patients.

AB - In the late 1950s, Sir James Black made a tremendous contribution to pharmacology and medicine with his discovery of â-blockers. After the first â-blockers became available in the 1960s, these drugs were noted to have beneficial effects in reducing morbidity and mortality from ischemic heart disease. It soon thereafter became apparent that blocking the adverse effects of the sympathetic nervous system could benefit many other diseases. As research and development continued, later generations of â-blockers appeared, each with unique properties such that it is now impossible to group these agents into one class to uniformly describe their effects. In this edition of Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications, the authors examine how â-blockers have evolved from their origin as a treatment for angina to a myriad of other elated and unrelated medical conditions. These include (in order of appearance), heart failure, hypertension, sepsis, tachydysrhythmias, portal hypertension, variceal bleeding, stimulant toxicity, thyrotoxicosis, obstructive lung disease, trauma, pheochromocytoma, cancer, acute coronary syndromes, and coronary arterial disease. The authors of these chapters hail from a spectrum of medical specialties as diverse as the indications for â-blockers: anesthesiology, cardiology, critical care, emergency medicine, gastroenterology, hematology/oncology, internal medicine, pharmacology, pulmonology, surgery, and toxicology. In this book, we also discuss controversies as well as the evolving and changing indications and contraindications for the use of this amazing class of drugs. This book will be of interest to physicians, pharmacists, nurse practitioners, physician assistants, nurses, research scientists, and informed patients.

UR - http://www.scopus.com/inward/record.url?scp=85048392420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048392420&partnerID=8YFLogxK

M3 - Book

AN - SCOPUS:85048392420

SN - 9781536133110

BT - Beta-blockers

PB - Nova Science Publishers, Inc.

ER -